Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

Trial Profile

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary) ; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Acronyms StatVax
  • Most Recent Events

    • 24 Jan 2019 Primary endpoint (fold change in total anti-pneumococcal antibody titer between treatment groups.) has been met as per results published in the Vaccine
    • 24 Jan 2019 Results published in the Vaccine
    • 25 Sep 2015 Phase is changed fro 4 to 1 as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top